The Safety of Intrathecal Therapy in the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)Phavina A Akhom, Adetola A. Kassim, Brittney Baer et al.|Transplantation and Cellular Therapy|2025Cited by 2
Brexucabtagene Autoleucel in the Outpatient Setting, a Single Institution ExperienceDavid Morgan, Phavina A Akhom, Brian Hoeynck et al.|Transplantation and Cellular Therapy|2025Cited by 0
Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center AnalysisGrace Mercadante, Shakthi Bhaskar, Phavina A Akhom et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outpatient Chimeric Antigen Receptor T cell Therapy in Patients Who Resided at Their Home Compared to Hospital-Provided Housing: A Single Institution ExperienceEmmanuella Iyore Osamuyi, Eden Biltibo, Grace Johnson Mercadante et al.|Transplantation and Cellular Therapy|2026Cited by 0